Please assess the completion status of the following clinical trial:

Trial Title: Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Low Back Pain (LBP) of non-malignant origin present for at least 3 months immediately before study entry~* Taking drug treatment for pain for at least 3 months before screening and who are dissatisfied with current therapy~* Subjects receiving opioid treatment must have a total daily opioid dose \<= 160 mg/day of oral morphine equivalent~* For entry into open label period patients must have a baseline score \>=5 on an 11-point NRS, calculated as the average pain intensity during the last 3 days of the washout period~* For entry into the double-blind period subjects must have remained on the same optimal stable dose and frequency of tapentadol (CG5503) IR administration during the last 3 days of the open-label treatment period~Exclusion Criteria:~* Presence of conditions other than Low Back Pain (LBP) that could make it hard to assess or self-evaluate pain~* Surgery in low back area within 3 months of screening or expected surgery in the low back area during the study~* Any scheduled surgery or painful procedure during the study, or any clinically significant disease that, in the opinion of the investigator, may affect efficacy or safety assessments~* History of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been treated and is no longer present~* Women who are pregnant or breast-feeding~* Moderately or severely impaired liver function~* Severely impaired kidney function~* History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C in past 3 months~* History of seizure disorder~* Alcohol or drug abuse~* Uncontrolled high blood pressure~* Clinically relevant history of hypersensitivity, allergy, or contraindications to acetaminophen or opioid analgesics (or ingredients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
- 002 (Type: EXPERIMENTAL): tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second

Based on this trial design, predict the completion outcome and termination type (if applicable).